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A COVID-19 vaccine has been framed as the ultimate solution needed to end the 
pandemic. A substantial number of vaccine candidates are in development, and several 
are undergoing clinical trials, with the first promising results recently published.1 While 
this provides hope as part of a solution to the pandemic it also raises concerns over how 
vaccines will be deployed and accepted. One challenge is ‘vaccine hesitancy.’ Evidence 
suggests that the public health benefits of approved COVID-19 vaccines will be 
undermined by hesitancy from populations to be vaccinated.2–9 Evident in the 
emergence of the new discipline of ‘infodemiology’ and ‘misinfodemic debates’10,11, there 
is an assumption that this reticence is primarily driven by people’s exposure to 
misinformation and that this can be countered by ‘inoculating’ publics with facts.12 
This brief draws on social science literature and informal interviews with experts to 
illustrate that vaccine hesitancy is more complex and context-specific, and often reflects 
diverse, everyday anxieties – not just, or even primarily, exposure to misinformation or 
anti-vaccine campaigners.  Based on this, the brief proposes strategies to guide policy 
makers, public health officials, vaccine developers, health workers, researchers, advocates, 
communicators, media actors and others involved in vaccine development, 
communication and deployment to boost confidence in COVID-19 vaccines. This brief is 
part of the Social Science in Humanitarian Action Platform (SSHAP) series on social 
science considerations relating to COVID-19 vaccines, and was written by Tabitha Hrynick, 
Santiago Ripoll, and Megan Schmidt-Sane. The brief is the responsibility of SSHAP. 
VACCINE HESITANCY AND CONFIDENCE 
VACCINE HESITANCY 
While vaccines are celebrated as one of the most successful public health measures, an 
increasing number of people believe vaccines are either unsafe or unnecessary. it is 
considered a growing threat to the success of vaccination programmes as vaccine 
coverage rates are decreasing globally.14 In 2019, the World Health Organization (WHO) 
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identified it as a top threat to global health.17 The WHO defines vaccine hesitancy as a ‘delay 
in acceptance or refusal of vaccines despite the availability of vaccination services’.18 It is a 
continuum ranging from complete acceptance to complete refusal.13,15,19 A Working Group 
on Vaccine Hesitancy in the UK Scientific Advisory Group for Emergencies  further defines 
it as:  A behaviour, influenced by a number of factors including issues of confidence [do 
not trust vaccine or provider], complacency [do not perceive a need for a vaccine, do not 
value the vaccine], and convenience [access].19 
The working group delineated determinants of vaccine hesitancy along three domains:  
Individual and 
group influences 
Personal perceptions of the vaccines or influences of the social 
environment 
Contextual 
influences 
Historic, socio-cultural, environmental, health system/institutional, 
economic or political factors 
Vaccine and 
vaccination 
Issues related to the characteristics of the vaccine, vaccine 
development, or the vaccination process 
Additional behavioural factors may shape vaccine uptake, including complacency 
(perception of risk, severity of disease), sources of information,20 socio-demographic 
characteristics,5 people’s level of commitment to risk culture and their level of confidence 
in health authorities and mainstream medicine.21 
VACCINE CONFIDENCE 
Conversely, vaccine confidence is the belief that vaccination, and the providers, private 
sector, and political actors behind it, serve the public’s best health interests.22 Like 
‘hesitancy,’ it is highly variable and rooted in political-economic context.23,24 Provision of 
consistent and scientifically accurate information can mediate some vaccine hesitancy, 
but vaccine confidence may not improve unless efforts are made to increase public trust 
in vaccine effectiveness and safety, in public health response, and in health systems and 
government more broadly.23,24  
EVOLUTION OF VACCINE HESITANCY AND CONFIDENCE 
Vaccine hesitancy is nothing new, indeed it is as old as vaccination.13–16 In 18th century 
Europe, many viewed vaccination as ‘against God’s plan.’ The following century saw the 
emergence of an Anti-Vaccination League in Britain.25 In the early 20th century in some 
African settings, colonial authorities forced vaccination onto populations, provoking 
resistance.26 By the 1970s, anti-vaccination gained further traction in Western settings 
following a report27 (later refuted) on adverse reactions to the pertussis vaccine. Since the 
late 1990s, hesitancy has been further spurred by controversy over alleged (since 
scientifically refuted) links between the MMR vaccination and autism.28,29 In the 1990s and 
early 2000s rumours emerged linking vaccines to infertility derailing vaccination efforts 
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in West Africa.30 When placed in historical perspective, two patterns emerge: first, that 
vaccines have been perceived to  cause more harm than the diseases they are intended 
to prevent; and second, that much of this concern is rooted in tensions between citizens 
and authorities, often resulting from compulsory vaccination policies.31–33 
Despite an abundance of scientific data on the safety and effectiveness of existing 
vaccines, alternative narratives have continued to emerge in the 21st century, driving 
vaccine hesitancy.34 These are often driven by  certain types of negative information used 
to discuss vaccine issues. Broadly these can be categorised as: 
Misinformation: false or inaccurate information, including rumours, whether intended to 
deceive or not;35,36 and disinformation: intentionally false information, spread for political, 
economic or social gain and conspiracy theories: alternative explanations for events; 37,38 
These types of information typically thrive during times of uncertainty (such as during 
epidemics), have been linked to lower likelihood of adopting public health behaviours, 
including vaccination and often spread fast, particularly via social media. 13,14,36,37 People 
sometimes use misinformation to attempt to collectively solve problems in the absence 
of good information, including when information from authorities is contradictory or 
incoherent.36 
SOCIAL SCIENCE LESSONS ON VACCINE HESITANCY  
Social science researchers during previous epidemics have illustrated that vaccine 
hesitancy is shaped by additional and complex dimensions beyond information alone. 
Consideration of the communities and contexts in which vaccination occurs, and what 
motivates people to participate, will be important considerations for COVID-19 vaccines. 
INDIVIDUAL AND GROUP INFLUENCES 
Information and knowledge. Debates about vaccine hesitancy often ignore sociocultural 
and political realities. They interpret publics as ignorant, subject to dis- or misinformation, 
and thus in need of ‘correct’ information. However, it is important to understand the 
broader contexts in which the different forms of information emerge and thrive. They do 
not emerge in vacuums, but from ecosystems of ‘culture, politics, personal experiences, 
beliefs, and histories’.36 A narrow interpretation of publics as ‘blank slates’ misses the 
reasons why people interpret information in particular ways.  People are diverse, with 
individual health, social and political experiences that influence the way they feel about 
vaccination. For example, individuals may accept some vaccines while refusing others, 
they may have genuine concerns about the trustworthiness of government and public 
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health response,39 scepticism of the role of ‘scientific experts,’40 historical experiences of 
marginalisation41 or militarised of vaccine deployment42 and so on.  
Social and cultural notions of the body, immunity and strength. Different social groups 
also have varying notions of immunity and strength, which influence how they relate to 
vaccination. This varies widely across and within countries. For instance, vaccines may be 
perceived as too ‘strong’, or to attack the body and impede natural immunity.43 Concerns 
can also arise about vaccine antigens and adjuvants, which can be perceived to be toxic 
or too immunogenic, as happened in Canada during the H1N1 2009 pandemic.44 There 
are examples of successful vaccination campaigns and trials which, have taken these 
notions into account and used local terms and concepts with positive outcomes for 
vaccine confidence and uptake.30 For example, frontline workers used local concepts of 
‘soldiers in the blood’ and ‘strength’ to explain how vaccinations work with potential trial 
participants in the Gambia.30 
Community dimensions of trust. Trusted local actors shape people’s perceptions of 
vaccines and vaccination programmes. Local healthcare providers for instance, are often 
best placed to deliver vaccinations in ways that build confidence. In contrast, mass 
vaccination campaigns led by unfamiliar, external actors have resulted in fear and 
reticence, as occurred for example, during polio vaccinations in Nigeria,30 and Ebola 
vaccine trials in the Democratic Republic of the Congo (DRC).45 However, people may also 
generally mistrust health services. In Sierra Leone, experiences of humiliation and 
marginalisation at health centres, coupled with worries about financial costs, led to 
people avoiding health centres altogether, and even hiding their children during 
immunisation campaigns.46  
Especially in low- and middle-income countries (LMICs), people may trust and rely on a 
range of non-biomedical health providers (traditional, faith or herbal healers, drug sellers, 
etc.), some of whom may feel threatened by, and thus also discourage vaccination. Some 
religious authorities too, have discouraged vaccination among followers, sometimes 
advocating faith healing instead. However, where religious leaders and traditional healers 
have been involved in vaccination programmes from their inception, they have gone on 
to be positive advocates for vaccination in their communities.47,48 
CONTEXTUAL INFLUENCES: POLITICAL ECONOMY AND TRUST 
Historical and political experiences of neglect, discrimination or abuse provide fertile 
ground for misinformation to gain traction and become ‘plausible’.49 Vaccine hesitancy is 
more likely to develop in contexts with high inequality and lack of citizen participation in 
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government and health systems, as people may perceive the state (and its partners) to 
have ulterior (and harmful) motives for vaccination.39  
Political or social divides. Vaccination has been perceived to cause intentional harm to 
particular groups or be a way of controlling them. In Northern Nigeria and Niger for 
example, Islamic leaders interpreted polio vaccination as a way of sterilising Muslims, and 
linked this to repression by the central government and to ‘Western’ attempts to stop 
their populations from growing.23,50,51  
Militarisation of vaccine campaigns. Many vaccination campaigns have been militarised, 
mirroring or actively involving military efforts (or police) to deploy vaccines.30,52 While this 
may be logistically effective, it may exacerbate fear and mistrust, particularly in settings 
where militaries are associated with repression and abuse.53  
Mandatory vaccination. Populations that have experienced mandatory vaccination (or 
other coercive public health measures), or have felt mistreated or exploited by drug trials, 
are less likely to trust future vaccination programmes.30 While the acceptability of coercive 
vaccination varies by context mandatory vaccination can improve overall uptake, but also 
entrench distrust in vaccine hesitant populations.54,55 Stories about profit-seeking and 
pharmaceutical companies in cahoots with governments can magnify this distrust.  
VACCINES AND VACCINATION 
Accessibility. It is important to distinguish lack of access or inadequate vaccine services 
from vaccine hesitancy. Work or care demands on people’s time, lack of physical access 
to vaccination posts, inadequate logistics, resource limitations, conflict or insecurity may 
be behind what may seem to be a lack of demand for vaccination. In contexts of extreme 
poverty, high burden of other diseases, or conversely, low burden of the epidemic disease, 
vaccination may be low on people’s list of priorities.19,56  
Perceptions of disease and vaccine risk . In conditions of uncertainty, individuals are likely 
to make choices based on perceived risk of a disease itself versus the risks of vaccination. 
The dynamics of a disease outbreak (e.g., real and perceived exposure and transmission 
rates) will differ across contexts, and shape people’s risk assessments.  
Different vaccines have different degrees of effectiveness in terms of percentage of 
reduction in disease incidence in the vaccinated group compared to an unvaccinated 
group under optimal conditions; this is never 100%. This may cause confusion over why 
some get infected despite being vaccinated.57  Trust in a vaccine can also diminish if 
people perceive it to have low effectiveness (e.g. H1N1 vaccine in Europe and the United 
States).58   
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Reports of adverse events, however unusual, can generate or deepen mistrust. People 
may attribute other unrelated diseases or health problems which emerge around the 
vaccination period to the vaccine. People may also worry about whether a vaccine 
is unsafe for some groups (e.g. elderly, infants, children, pregnant women, different 
ethnic groups).  
Vaccine hesitancy sometimes arises  amongst healthcare workers, particularly so in the 
case of vaccines rapidly developed in an emergency. For example, some healthcare 
workers distrusted or refused the Ebola vaccine in the DRC, and European healthcare 
workers were unsure about the safety H1N1 2009 vaccine.45,59 
Perceptions of vaccine roll-out. Who is eligible and prioritised to receive vaccines has led 
to mistrust of vaccination programmes in the past. Research during the DRC Ebola 
epidemic (2018-2019) found that where only healthcare workers were given vaccines, 
others expressed a strong desire to be vaccinated and were upset they were excluded.60 
The mode of service delivery (mobile or fixed clinics, vaccination combined with other 
human or animal health services) shapes confidence and uptake, and different groups 
will have different preferences.61 Vaccination services have been more successful where 
local gender and cultural sensitivities have been incorporated.62 Incentives for attendance 
can increase uptake, but also backfire if inequitably distributed, stoking pre-existing 
perceptions of injustice.51 
The coexistence of several vaccines in the same context can lead to mistrust. Two different 
vaccines were rolled out simultaneously in an Ebola outbreak in North Kivu, DRC; there 
were different requirements for vaccine transport and delivery, number of doses and 
eligibility, and different vaccination protocols (mass vaccination versus ring vaccination). 
This generated confusion and anxieties.63,64  
VACCINATION FOR COVID-19 
EVIDENCE OF COVID-19 VACCINE HESITANCY 
For a COVID-19 vaccine to stem the pandemic, experts suggest 80-90% of the population 
require vaccination.5 Yet, surveys emerging from diverse contexts illustrate widespread 
hesitancy towards COVID-19 vaccines, with large differences between and within 
countries.3,5–7,9 Recent studies of 19 countries, the proportion of people reporting they 
would accept a ‘proven, safe and effective vaccine’ ranged from nearly 90% in China to 
55% in Russia.3 In another, 36% and 51% of survey respondents in the UK and US 
respectively reported they were ‘uncertain’ or unlikely to be vaccinated.5  
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The complex range of social, political, economic and cultural factors that always affect 
vaccine uptake will also affect COVID-19 vaccines, alongside many new challenges. While 
there are some key factors likely to drive hesitancy in similar ways across settings, these 
dynamics are also highly-context specific.  
CHALLENGES FOR COVID-19 VACCINE CONFIDENCE   
Expedited development and novelty of COVID-19 vaccines 
◼ Vaccine safety and effectiveness testing. The speed of vaccine development and trials 
is a major driver of COVID-19 vaccine hesitancy as it undermines some people’s 
confidence that sufficient testing for effectiveness and safety is being carried out prior 
to approval for use in populations.  
◼ Novel platforms. Many COVID-19 vaccines are being manufactured using entirely new 
platforms,65 potentially deepening people’s reservations about their safety. DNA and 
mRNA platforms in particular, may trigger anxieties and concern.66 
◼ Lack of safety records for approved vaccines. Once approved, COVID-19 vaccines will 
lack long-term safety records which may make many people nervous about taking 
them until they have been safely in use for some time. Adverse events resulting from 
a vaccine, or seeming to result from it, can also damage vaccine confidence.67,68  
◼ Uncertainties around COVID-19. There remain many unknowns about the SARS-CoV-
2 virus, and COVID-19. This may undermine people’s confidence that it is possible to 
successfully manufacture safe and effective vaccines while still lacking some 
understanding of the virus, its transmission, and disease.  
◼ Uncertainties about new vaccines. The duration of immunity offered by new vaccines 
is still unknown. Likewise as new vaccines are approved, information about the type 
of protection (preventing disease and/or preventing transmission, including in 
different demographic groups) will lag.5,69 
◼ Lack of transparency on vaccine development and trials. Pharmaceutical companies 
do not often publish trial protocols or release results as this may compromise trial 
methodology (e.g. blinding) or damage their market competitiveness. A lack of 
transparency can undermine confidence, giving rise to conspiracy theories, and 
reinforcing pre-existing public mistrust towards the pharmaceutical industry.70 
◼ Small and unknown developers. Although many people may mistrust large 
pharmaceutical companies, many of the hundreds of COVID-19 vaccines in 
development are being produced by smaller, lesser known manufacturers which may 
also undermine confidence.71 
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Information and Communication Environments and Efforts  
◼ Social media and exposure to false information. The expansion of social media use 
provides opportunities for COVID-19 vaccine and misinformation to spread.72 This 
occurs alongside the spread in offline channels as well, especially in contexts where 
internet access is limited. Researchers illustrated that exposure to misinformation can 
result in lower reported intent to vaccinate for COVID-19, even among people who 
previously reported ‘definitely’ intending to vaccinate in the UK and US.8 In African 
settings, rumours that Africans would be experimented on or poisoned with Western 
vaccines spread via social media.73,74 As suggested, different narratives may emerge 
and provoke particular anxieties in different contexts and groups.  
◼ Storytelling and emotion versus facts and traditional authority. Many people are more 
drawn to the ‘speed, emotion and memorable stories’ increasingly favoured by 
modern media providers than to more fact-based material and appeals to traditional 
forms of authority.68,75  
◼ Scientific authority. Misinformation that sounds scientific, or, hesitancy which is 
expressed by people with expert medical knowledge, such as healthcare workers, can 
affect vaccine confidence. For example, healthcare workers who feel hesitancy 
towards COVID-19 vaccines,76,77 can be explicitly or implicitly transferred to patients 
(for instance, by not answering their questions sufficiently).78 
◼ Challenge of communicating vaccine complexities. There are likely to be several 
COVID-19 vaccines available, with different levels of effectiveness, risk profiles, modes 
of delivery, prioritisation schemes, vaccine schedules and safety requirements. The 
complexities of introducing multiple vaccines in a short period can cause confusion 
and frustration if not communicated effectively.5  
The Politicisation of COVID-19 Vaccine Development and Deployment 
◼ Harmful politicisation of vaccine development. Vaccine development has become 
entangled with national and international politics with some governments desiring 
to be seen to develop and deliver the first viable COVID-19 vaccines.75,79,80 This can 
undermine confidence, including by raising concerns about rushed development.  
◼ Political attempts to control COVID-19 narratives. To keep publics calm or to maintain 
a perception of control, some governments have downplayed the pandemic, and 
repressed news or rumours about COVID-19 even when they turn out to be true (e.g. 
regarding the existence or extent of an outbreak and community transmission).81 
These can undermine public trust and thus vaccine confidence.  
◼ Governments’ previous handling of COVID-19 response may undermine vaccine 
confidence. For instance: coercive measures, the extent to which people have been 
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supported to meet their basic needs amidst financial losses, the conduct of 
government officials, the clarity of information, the success of interventions such as 
testing or contact tracing, or suspicions that government officials or connected 
private entities are profiting from response activities.    
◼ Marginalised communities. Marginalised communities (e.g., ethnic or religious 
minorities and the poor) who have experienced neglect or abuse by the state or health 
system may have less confidence in COVID-19 vaccines and the institutions and 
experts who communicate and administer them. This is exacerbated when health 
information is not adapted to local languages or people have little access to health 
services, as in the case of refugees. In the US for instance, COVID-19 vaccine hesitancy 
is highest among Black communities.2,7 Rumours and conspiracy theories may have 
more traction among marginalised groups because of prior experiences of exclusion 
that make these more plausible.  
◼ Other communities. Not all communities with low vaccine confidence are 
marginalised. Many people of different income groups, education levels and contexts 
are wary of biomedicine or prefer ‘natural’ or ‘traditional’ methods and may refuse 
COVID-19 vaccines, as they have others.  
◼ Worries about being experimented on. Evidence suggests people in some African 
settings may be worried they are being experimented on with vaccines.6 For example, 
comments from a researcher earlier in the pandemic, that vaccines for COVID-19 
should first be trialled on African populations, likely contributed to this.13 
WAYS TO INCREASE COVID-19 VACCINE CONFIDENCE  
To date, governments and public health actors have been more focused on vaccine 
development, than building up vaccine confidence. Below are strategies and approaches 
that can help policymakers, public health officials, vaccine developers, healthcare 
workers, researchers, advocates, communicators, media and others to build and sustain 
public confidence in – and thus future uptake of – COVID-19 vaccines. Multi-pronged 
approaches, tailored to socio-political contexts, specific social groups and even 
individuals, are likely to yield the best results.78 
DEVELOPMENT AND APPROVAL   
It is imperative to build up public trust while the increasing numbers of vaccines entering 
trial and approval stages edge closer to deployment.   
◼ Engage a ‘good politics’ around vaccine development and approval (as well as 
deployment). It is impossible to avoid ‘politicisation’ as political decisions are necessary 
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to act. However, this should be done through transparency, accountability, and 
democratic and participatory engagement around vaccination, and the broader 
public health response.    
◼ Exercise transparency as far as possible in trial processes. Clearly communicate 
information and data in accessible formats. Share trial protocols and results where 
possible (including explanations when adverse medical events occur). Share what 
vaccines are made of, and how they should work.     
◼ Pledges to vaccine safety. Nine vaccine manufacturers recently pledged not 
to submit vaccines for approval in the US until proven safe in large clinical trials to 
assuage fears around political pressure to speed up development.82 This could be 
scaled and/or adapted, including among different stakeholder groups to add an 
additional layer of reassurance for the public. 
CREATIVE COMMUNICATION AND HONEST DIALOGUE   
◼ Be imaginative and compelling with communications, including story-telling (e.g. 
personal stories to which people can relate), emotion, appeals to empathy and 
altruism, as well as memes to convey key information in engaging ways.75,83 This 
requires context-specific assessment to identify communication preferences and 
language needs.  Accessible material can help people make sense of things in the 
inherently uncertain and tense time 
◼ Use a wide range of platforms, both off and online, including social media, for clear  
communication about the types of vaccines and the process of deploying them. Use 
all languages spoken, and visual imagery from the platforms people trust.   
◼ Build on local terminologies and understandings of vitality, strength and immunity in 
communications about vaccination.   
◼ Remind the public to act responsibly and think about accuracy prior to posting or 
sharing information verbally or online social media.84  
◼ Use open dialogue, it is important to field questions and address anxieties from 
people and to listen to their concern and priorities. These should be responded to 
into other vaccination related activities.85 Successful models have been carried out in 
the context of Ebola vaccine trials in Sierra Leone.39 
◼ Be honest about uncertainties, what is known and what isn’t, and do not assume 
publics can only deal with simple information. Communication of complex issues can 
be achieved using dialogue, and locally appropriate ways of designing and further 
disseminating messages can also emerge from these discussions. 
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◼ Patient-centred motivational techniques in patient-healthcare worker encounters 
(vis-à-vis more confrontational approaches) may help vaccine confidence through 
empathetic listening and avoiding rebuttal of ‘false opinions’.78  
ACTING TOGETHER  
◼ Work with trusted influencers in and beyond public health – from national and 
international celebrities, to online ‘influencers’, to locally trusted alternative health 
providers and leaders – to convey information and facilitate dialogue in compelling 
ways. Remember that it is not always obvious who is locally trusted.   
◼ Co-design and discuss vaccination strategies with citizens, including how to prioritise 
access once vaccines are available. Prioritisation may be done geographically (e.g. 
where there is higher transmission or risk), by occupational group (e.g. prioritising 
frontline personnel), by age or medical status (e.g. the elderly, people with pre-existing 
conditions). This will be important for building and maintaining public trust and 
confidence, especially where vaccine confidence is already low. Citizens juries are a 
useful model used in past epidemics.86,87 
◼ Work with frontline healthcare workers, including non-biomedical health providers to 
address vaccine hesitancy among them, ensuring they are confident to communicate 
effectively about COVID-19 vaccines.78  
MONITORING VACCINE CONFIDENCE   
Different types of monitoring efforts should reinforce one another, and together should 
directly inform engagement with communities. 
◼ Continue quantitative surveys to continually assess vaccine hesitancy and confidence, 
and monitor this for changes, including by social group (by gender, age, ethnicity, 
location etc.).  Extra focus and resourcing are required for surveys in LMICs . 
◼ Qualitative research of vaccine hesitancy and confidence is crucial to inform strategy 
and policy. Rapid, formative, and in-depth social science investigation can enable 
contextual understanding of the root causes, features, and trajectories of hesitancy,.  
◼ Continuously collect and analyse feedback from communities to understand 
emerging and evolving misconceptions, rumours and concerns. In parallel, monitor 
perceptions of the vaccination campaigns and of the vaccination experience. 
◼ Track (and address) dis- and misinformation on and offline and assess its risks to 
vaccine confidence, e.g. by considering whether the communities it is circulating in 
are marginalised. Harmonise independent efforts to do this within regions or areas. 
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VACCINE DEPLOYMENT 
◼ Rapidly increase communication, dialogue and planning with communities as soon 
as possible about what vaccine deployment may look like, especially when there are 
complexities of multiple vaccines, deployed and working in different ways. 
◼ Manage expectations of likely vaccine effectiveness, of who will be prioritised, and that 
life may not go ‘back to normal’ for some time after vaccines are deployed.69 
◼ Avoid coercive strategies as this can backfire by damaging trust, inducing hesitancy 
and entrenching resolve against vaccination. 
◼ Ensure vaccines are administered by trusted actors such as local healthcare providers, 
including non-biomedical practitioners where appropriate, and avoid deploying the 
military. Use existing infrastructures as far as possible (such as for routine vaccine 
drives), as this may inspire greater trust and confidence.5 
◼ Ensure everyone that needs the vaccine is included in vaccination plans. Ensure 
minority and marginalised communities, refugees and migrants whose status may 
jeopardize their access to health services are included. 
◼ Take vaccination to places people are comfortable such as shopping centres, 
workplaces, schools, religious sites etc., especially in minority communities who might 
be reluctant to visit health facilities. 
◼ Ensure surveillance systems for adverse medical events which may be caused, or 
perceived to be caused, by vaccines are in place. Engage independent monitoring 
bodies at national and regional level, and establish clear communication protocols for 
communicating with publics about adverse events.67 
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ADDITIONAL RESOURCES 
The Vaccine Confidence Project aims to monitor and build public confidence in 
immunisation programmes, including for COVID-19 through its CONVINCE (COVID-19 
New Vaccine Information Communication and Engagement) initiative 
https://www.vaccineconfidence.org/   
Social Science Research for Vaccine Deployment in Epidemic Outbreaks 
https://opendocs.ids.ac.uk/opendocs/bitstream/handle/20.500.12413/15431/PracApproach
%206.pdf?sequence=2&isAllowed=y 
Sociocultural Considerations for Vaccine Introduction and Community Engagement 
https://shsebola.hypotheses.org/files/2018/09/Anthrologica-key-considerations-for-
vaccine-introduction-in-DRCIRDRAEE.pdf   
Clinical and Vaccine Trials for COVID-19: Key Considerations from Social Science 
https://www.socialscienceinaction.org/resources/clinical-and-vaccine-trials-for-covid-19-
key-considerations-from-social-science/  
Community Engagement and Accountability Toolkit (IFRC) 
https://media.ifrc.org/ifrc/document/community-engagement-and-accountability-
toolkit/   
Guidance on National Deployment and Vaccination Planning (WHO) 
https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccine_deployment-2020.1   
COVID-10 Vaccine Introduction Readiness Assessment Tool (WHO) 
https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccine-introduction-RA-
Tool-2020.1  
Online Information, Mis- and Disinformation in the Context of COVID-19 (SSHAP) 
https://www.socialscienceinaction.org/resources/key-considerations-online-information-
mis-disinformation-context-covid-19/   
 
 
 
 
 
RAPID REVIEW: VACCINE HESITANCY AND BUILDING CONFIDENCE IN COVID-19 VACCINATION 
Contact:  t.hrynick@ids.ac.uk 14 
REFERENCES 
1. Boseley, S., & Oltermann,  and P. (2020, November 9). Covid-19 vaccine candidate is 90% effective, says 
manufacturer. The Guardian. https://www.theguardian.com/world/2020/nov/09/covid-19-vaccine-
candidate-effective-pfizer-biontech 
2. Baum, M. A., Ognyanova, K., Chwe, H., Quintana, A., Perlis, R. H., Lazer, D., Druckman, J., Santillana, M., Lin, J., 
Della Volpe, J., Simonson, M., & Green, J. (2020). The state of the nation: A 50-state survey report 14: 
Misinformation and vaccine acceptance. The COVID-19 Consortium for Understanding the Public’s 
Policy Preferences Across States. 
3. Lazarus, J. V., Ratzan, S. C., Palayew, A., Gostin, L. O., Larson, H. J., Rabin, K., Kimball, S., & El-Mohandes, A. 
(2020). A global survey of potential acceptance of a COVID-19 vaccine. Nature Medicine, 1–4. 
https://doi.org/10.1038/s41591-020-1124-9 
4. Roozenbeek, J., Schneider, C. R., Dryhurst, S., Kerr, J., Freeman, A. L. J., Recchia, G., van der Bles, A. M., & van 
der Linden, S. (n.d.). Susceptibility to misinformation about COVID-19 around the world. Royal Society 
Open Science, 7(10), 201199. https://doi.org/10.1098/rsos.201199 
5. The Royal Society, & The British Academy. (2020). COVID-19 vaccine deployment: Behaviour, ethics, 
misinformation and policy strategies [Preprint]. 
6. Partnership for Evidence-Based COVID-19 Response (PERC). (n.d.). Responding to COVID-19 in Africa: Using 
Data to Find a Balance (Part II). Retrieved 16 November 2020, from https://preventepidemics.org/wp-
content/uploads/2020/09/PERC_RespondingtoCovidData.pdf 
7. Tyson, A., Johnson, C., & Funk, C. (2020, September 17). U.S. Public Now Divided Over Whether To Get COVID-
19 Vaccine. Pew Research Center Science & Society. 
https://www.pewresearch.org/science/2020/09/17/u-s-public-now-divided-over-whether-to-get-
covid-19-vaccine/ 
8. Loomba, S., Figueiredo, A. de, Piatek, S. J., Graaf, K. de, & Larson, H. J. (2020). Measuring the Impact of 
Exposure to COVID-19 Vaccine Misinformation on Vaccine Intent in the UK and US. MedRxiv, 
2020.10.22.20217513. https://doi.org/10.1101/2020.10.22.20217513 
9. Johns Hopkins Center for Communication Programs. (2020). KAP COVID Global View. Johns Hopkins 
Center for Communication Programs. https://ccp.jhu.edu/kap-covid/kap-covid-global-view-2/ 
10. McGinty, M., & Gyenes, N. (2020). A dangerous misinfodemic spreads alongside the SARS-COV-2 
pandemic. Harvard Kennedy School (HKS) Misinformation Review, 1(3). 
https://misinforeview.hks.harvard.edu/article/a-misinfodemic-as-dangerous-as-sars-cov-2-
pandemic-itself/ 
11. Meedan. (n.d.). 2020 Misinfodemic Report: COVID-19 in Emerging Economies. Meedan. Retrieved 12 
November 2020, from /reports/2020-misinfodemic-report-covid-19-in-emerging-economies/ 
12. van der Linden, S., Roozenbeek, J., & Compton, J. (2020). Inoculating Against Fake News About COVID-19. 
Frontiers in Psychology, 11. https://doi.org/10.3389/fpsyg.2020.566790 
13. Bhopal, S., & Nielsen, M. (2020). Vaccine hesitancy in low- and middle-income countries: Potential 
implications for the COVID-19 response. Archives of Disease in Childhood. 
https://doi.org/10.1136/archdischild-2020-318988 
14. Dubé, E., Laberge, C., Guay, M., Bramadat, P., Roy, R., & Bettinger, J. A. (2013). Vaccine hesitancy. Human 
Vaccines & Immunotherapeutics, 9(8), 1763–1773. https://doi.org/10.4161/hv.24657 
15. Dubé, E., Vivion, M., & MacDonald, N. E. (2015). Vaccine hesitancy, vaccine refusal and the anti-vaccine 
movement: Influence, impact and implications. Expert Review of Vaccines, 14(1), 99–117. 
https://doi.org/10.1586/14760584.2015.964212 
16. Szasz, G. (2020). Vaccine hesitancy: As old as vaccines | British Columbia Medical Journal. 
https://bcmj.org/blog/vaccine-hesitancy-old-vaccines 
17. WHO. (2019). Ten health issues WHO will tackle this year. https://www.who.int/news-room/spotlight/ten-
threats-to-global-health-in-2019 
18. Burki, T. (2019). Vaccine misinformation and social media. The Lancet Digital Health, 1(6), e258–e259. 
https://doi.org/10.1016/S2589-7500(19)30136-0 
19. Dubé, E., Gagnon, D., Nickels, E., Jeram, S., & Schuster, M. (2014). Mapping vaccine hesitancy—Country-
specific characteristics of a global phenomenon. Vaccine, 32(49), 6649–6654. 
https://doi.org/10.1016/j.vaccine.2014.09.039 
20. Edelman. (2020). Edelman Trust Barometer 2020. Global Report. Edelman. 
https://cdn2.hubspot.net/hubfs/440941/Trust%20Barometer%202020/2020%20Edelman%20Trust%2
RAPID REVIEW: VACCINE HESITANCY AND BUILDING CONFIDENCE IN COVID-19 VACCINATION 
Contact:  t.hrynick@ids.ac.uk 15 
0Barometer%20Global%20Report.pdf?utm_campaign=Global:%20Trust%20Barometer%202020&ut
m_source=Website 
21. Peretti-Watel, P., Larson, H. J., Ward, J. K., Schulz, W. S., & Verger, P. (2015). Vaccine Hesitancy: Clarifying a 
Theoretical Framework for an Ambiguous Notion. PLoS Currents, 7. 
https://doi.org/10.1371/currents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289 
22. The Vaccine Confidence Project. (n.d.). The Vaccine Confidence Project. Retrieved 9 November 2020, from 
https://www.vaccineconfidence.org/vcp-mission 
23. Larson, H. J., Cooper, L. Z., Eskola, J., Katz, S. L., & Ratzan, S. (2011). Addressing the vaccine confidence gap. 
The Lancet, 378(9790), 526–535. https://doi.org/10.1016/S0140-6736(11)60678-8 
24. Larson, H. J., Schulz, W. S., Tucker, J. D., & Smith, D. M. D. (2015). Measuring Vaccine Confidence: Introducing 
a Global Vaccine Confidence Index. PLOS Currents Outbreaks. 
https://doi.org/10.1371/currents.outbreaks.ce0f6177bc97332602a8e3fe7d7f7cc4 
25. Hussain, A., Ali, S., Ahmed, M., & Hussain, S. (2018). The Anti-vaccination Movement: A Regression in Modern 
Medicine. Cureus, 10(7). https://doi.org/10.7759/cureus.2919 
26. Schneider, W. H. (2009). Smallpox in Africa during Colonial Rule. Medical History, 53(2), 193–227. 
27. Kulenkampff, M., Schwartzman, J. S., & Wilson, J. (1974). Neurological complications of pertussis 
inoculation. Archives of Disease in Childhood, 49(1), 46–49. 
28. Kolodziejski, L. R. (2014). Harms of Hedging in Scientific Discourse: Andrew Wakefield and the Origins of 
the Autism Vaccine Controversy. Technical Communication Quarterly, 23(3), 165–183. 
https://doi.org/10.1080/10572252.2013.816487 
29. Rao, T. S. S., & Andrade, C. (2011). The MMR vaccine and autism: Sensation, refutation, retraction, and fraud. 
Indian Journal of Psychiatry, 53(2), 95–96. https://doi.org/10.4103/0019-5545.82529 
30. Leach, M., & Fairhead, J. (2007). Vaccine Anxieties: Global Science, Child Health and Society. Earthscan. 
31. Durbach, N. (2004). Bodily Matters: The Anti-Vaccination Movement in England, 1853–1907. Duke Univ. 
32. Schwartz, J. L. (2012). New Media, Old Messages: Themes in the History of Vaccine Hesitancy and Refusal . 
AMA Journal of Ethics, 14(1), 50–55. https://doi.org/10.1001/virtualmentor.2012.14.1.mhst1-1201. 
33. Wolfe, R. M., & Sharp, L. K. (2002). Anti-vaccinationists past and present. BMJ, 325(7361), 430–432. 
https://doi.org/10.1136/bmj.325.7361.430 
34. Geoghegan, S., O’Callaghan, K. P., & Offit, P. A. (2020). Vaccine Safety: Myths and Misinformation. Frontiers 
in Microbiology, 11. https://doi.org/10.3389/fmicb.2020.00372 
35. Center for Strategic and International Studies. (2020). The Risks of Misinformation and Vaccine Hesitancy 
within the Covid-19 Crisis. https://www.csis.org/analysis/risks-misinformation-and-vaccine-hesitancy-
within-covid-19-crisis 
36. Larson, H. J. (2020). Stuck: How Vaccine Rumors Start -- and Why They Don’t Go Away. OUP 
37. Wilson, S. L., & Wiysonge, C. (2020). Social media and vaccine hesitancy. BMJ Global Health, 5(10), e004206. 
https://doi.org/10.1136/bmjgh-2020-004206 
38. MacDonald, N. E. (2015). Vaccine hesitancy: Definition, scope and determinants. Vaccine, 33(34), 4161–4164. 
https://doi.org/10.1016/j.vaccine.2015.04.036 
39. Enria, L., Lees, S., Smout, E., Mooney, T., Tengbeh, A. F., Leigh, B., Greenwood, B., Watson-Jones, D., & Larson, 
H. (2016). Power, fairness and trust: Understanding and engaging with vaccine trial participants and 
communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone. BMC Public Health, 
16(1), 1140. https://doi.org/10.1186/s12889-016-3799-x 
40. Kennedy, J. (2019). Populist politics and vaccine hesitancy in Western Europe: An analysis of national-level 
data. European Journal of Public Health, 29(3), 512–516. https://doi.org/10.1093/eurpub/ckz004 
41. Kpanake, L., Sorum, P. C., & Mullet, É. (2018). Willingness to get vaccinated against Ebola: A mapping of 
Guinean people positions. Human Vaccines & Immunotherapeutics, 14(10), 2391–2396. 
https://doi.org/10.1080/21645515.2018.1480236 
42. Nichter, M. (2019). Vaccinations in South Asia: False Expectations and Commanding Metaphors (pp. 196–
221). https://doi.org/10.4324/9780429045936-14 
43. Smith, T. C. (2017). Vaccine Rejection and Hesitancy: A Review and Call to Action. Open Forum Infectious 
Diseases, 4(3), ofx146–ofx146. PubMed. https://doi.org/10.1093/ofid/ofx146 
44. Henrich, N., & Holmes, B. (2011). What the Public Was Saying about the H1N1 Vaccine: Perceptions and 
Issues Discussed in On-Line Comments during the 2009 H1N1 Pandemic. PLOS ONE, 6(4), e18479. 
https://doi.org/10.1371/journal.pone.0018479 
45. Carter, S. E., Mobula, L., Samaha, H., & Ahuka, S. M. (2020, October 22). Community engagement and 
vaccinations during the Ebola outbreak in Democratic Republic of Congo. World Bank Blogs. 
https://blogs.worldbank.org/health/community-engagement-and-vaccinations-during-ebola-
outbreak-democratic-republic-congo 
RAPID REVIEW: VACCINE HESITANCY AND BUILDING CONFIDENCE IN COVID-19 VACCINATION 
Contact:  t.hrynick@ids.ac.uk 16 
46. Enria, L., Bangura, J., Kanu, H., Kalokoh, J., Timbo, A., Kamara, M., Fofanah, M., Kamara, M., Suma, I. S., 
Kamara, O. M., Kamara, A., Kamara, A., Kamara, A. B., Kamara, E., Lees, S., Marchant, M., & Murray, M. 
(2020). Integrating community-led social science research into innovative strategies for tackling 
vaccine hesitancy: Findings from a pilot study with community health workers in Sierra Leone Enria. 
Paper in Preparation. 
47. Anderson, N., Wilson, N., Moon, T., Kanem, N., Diop, A., & Gbodossou, E. (2015). Redefining Immunization: 
Not Just a Shot in the Arm. Global Health Communication, 1(1), 1–9. 
https://doi.org/10.1080/23762004.2016.1161416 
48. Audet, C. M., Hamilton, E., Hughart, L., & Salato, J. (2015). Engagement of Traditional Healers and Birth 
Attendants as a Controversial Proposal to Extend the HIV Health Workforce. Current HIV/AIDS 
Reports, 12(2), 238–245. PubMed. https://doi.org/10.1007/s11904-015-0258-8 
49. Ripoll, S., & Wilkinson, A. (n.d.). Social Science in Epidemics: Cholera Lessons Learned. Social Science in 
Humanitarian Action (SSHAP). Retrieved 16 November 2020, from 
https://opendocs.ids.ac.uk/opendocs/handle/20.500.12413/14200 
50. Larson, H. J., & Ghinai, I. (2011). Lessons from polio eradication. Nature, 473(7348), 446–447. 
https://doi.org/10.1038/473446a 
51. Masquelier, A. (2012). Public Health or Public Threat?: Polio Eradication Campaigns, Islamic Revival, and 
the Materialization of State Power in Niger. In H. DILGER, A. KANE, & S. A. LANGWICK (Eds.), Medicine, 
Mobility, and Power in Global Africa (pp. 213–240). Indiana University Press; JSTOR. 
http://www.jstor.org/stable/j.ctt16gzgfc.12 
52. Tengbeh, A. F., Enria, L., Smout, E., Mooney, T., Callaghan, M., Ishola, D., Leigh, B., Watson-Jones, D., 
Greenwood, B., Larson, H., & Lees, S. (2018). “We are the heroes because we are ready to die for this 
country”: Participants’ decision-making and grounded ethics in an Ebola vaccine clinical trial. Social 
Science & Medicine, 203, 35–42. https://doi.org/10.1016/j.socscimed.2018.03.008 
53. Benton, A. (2017). Whose security? Militarization and securitization during West Africa’s Ebola outbreak. 
The Politics of Fear: Médecins sans Frontières and the West African Ebola Epidemic, 25–50. 
54. Bazylevych, M. (2011). Vaccination campaigns in postsocialist Ukraine: Health care providers navigating 
uncertainty. Medical Anthropology Quarterly, 25(4), 436–456. 
55. Holzmann, H., & Wiedermann, U. (2019). Mandatory vaccination: Suited to enhance vaccination coverage 
in Europe? Eurosurveillance, 24(26), 1900376. 
56. SAGE working group on vaccine hesitancy. (2014). Report of the SAGE working group on vaccine 
hesitancy. WHO. 
https://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vacci
ne_hesitancy_final.pdf 
57. Heyerdahl, L. W., Ngwira, B., Demolis, R., Nyirenda, G., Mwesawina, M., Rafael, F., Cavailler, P., Bernard Le 
Gargasson, J., Mengel, M. A., Gessner, B. D., & Guillermet, E. (2018). Innovative vaccine delivery strategies 
in response to a cholera outbreak in the challenging context of Lake Chilwa. A rapid qualitative 
assessment. Vaccine Hesitancy: Towards a Better Understanding of Drivers and Barriers to 
Awareness, Acceptance and Activation, 36(44), 6491–6496. https://doi.org/10.1016/j.vaccine.2017.10.108 
58. Forster, P. (2012). To Pandemic or Not? Reconfiguring Global Responses to Influenza (STEPS Working 
Paper 51). STEPS Centre. https://core.ac.uk/download/pdf/286038816.pdf 
59. Blasi, F., Aliberti, S., Mantero, M., & Centanni, S. (2012). Compliance with anti‐H1N1 vaccine among 
healthcare workers and general population. Clinical Microbiology and Infection, 18, 37–41. 
60. Kaawa-Mafigiri, D., & Schmidt-Sane, M. (2019). Strengthening Community Linkages to Ebola Virus Disease 
(EVD) Outbreak Preparedness in Uganda: Report on Anthropological Research on the Socio-Cultural 
Context of EVD in the Most-at-Risk Districts. UNICEF. 
61. Porta, M. I., Lenglet, A., de Weerdt, S., Crestani, R., Sinke, R., Jo Frawley, M., Van Herp, M., & Zachariah, R. 
(2014). Feasibility of a preventive mass vaccination campaign with two doses of oral cholera vaccine 
during a humanitarian emergency in South Sudan. Transactions of the Royal Society of Tropical 
Medicine and Hygiene, 108(12), 810–815. 
62. Jalloh, M. F., Bennett, S. D., Alam, D., Kouta, P., Lourenço, D., Alamgir, M., Feldstein, L. R., Ehlman, D. C., Abad, 
N., Kapil, N., Vandenent, M., Conklin, L., & Wolff, B. (2019). Rapid behavioral assessment of barriers and 
opportunities to improve vaccination coverage among displaced Rohingyas in Bangladesh, January 
2018. Vaccine, 37(6), 833–838. https://doi.org/10.1016/j.vaccine.2018.12.042 
63. Bardosh, K., Jones, T., & Tulloch, Olivia. (2019). Social science and behavioural data compilation (#5), Ebola 
outbreak eastern DRC, September-November 2019. Social Science in Humanitarian Action (SSHAP). 
https://www.socialscienceinaction.org/resources/social-science-behavioural-data-compilation-5-
ebola-outbreak-eastern-drc-september-november-2019/ 
RAPID REVIEW: VACCINE HESITANCY AND BUILDING CONFIDENCE IN COVID-19 VACCINATION 
Contact:  t.hrynick@ids.ac.uk 17 
64. Child, D. (2019, September 23). DRC: Roll-out of second Ebola vaccine confirmed amid criticism. Al Jazeera 
News. https://www.aljazeera.com/news/2019/9/23/drc-roll-out-of-second-ebola-vaccine-confirmed-
amid-criticism 
65. van Riel, D., & de Wit, E. (2020). Next-generation vaccine platforms for COVID-19. Nature Materials, 19(8), 
810–812. https://doi.org/10.1038/s41563-020-0746-0 
66. Reuters Staff. (2020, May 19). False claim: A COVID-19 vaccine will genetically modify humans. Reuters. 
https://uk.reuters.com/article/uk-factcheck-covid-19-vaccine-modify-idUSKBN22U2BZ 
67. Kochhar, S., & Salmon, D. A. (2020). Planning for COVID-19 vaccines safety surveillance. Vaccine, 38(40), 
6194–6198. https://doi.org/10.1016/j.vaccine.2020.07.013 
68. Salmon, D. A., & Dudley, M. Z. (2020). It is time to get serious about vaccine confidence. The Lancet, 
396(10255), 870–871. https://doi.org/10.1016/S0140-6736(20)31603-2 
69. Peiris, M., & Leung, G. M. (2020). What can we expect from first-generation COVID-19 vaccines? Lancet 
(London, England), 396(10261), 1467–1469. https://doi.org/10.1016/S0140-6736(20)31976-0 
70. Nature. (2020). COVID vaccine confidence requires radical transparency. Nature, 586(7827), 8–8. 
https://doi.org/10.1038/d41586-020-02738-y 
71. Fadda, M., Albanese, E., & Suggs, L. S. (2020). When a COVID-19 vaccine is ready, will we all be ready for it? 
International Journal of Public Health, 65(6), 711–712. https://doi.org/10.1007/s00038-020-01404-4 
72. Frenkel, S., Decker, B., & Alba, D. (2020). How the ‘Plandemic’ Movie and Its Falsehoods Spread Widely 
Online. The New York Times. https://www.nytimes.com/2020/05/20/technology/plandemic-movie-
youtube-facebook-coronavirus.html 
73. Africa Check. (2020, April 14). Bill Gates not testing Covid-19 vaccine in Africa. Africa Check. 
https://africacheck.org/fbcheck/bill-gates-not-testing-covid-19-vaccine-in-africa/ 
74. Africa Check. (2020, April 6). No, former US president Obama didn’t warn Africans against coronavirus 
vaccines. Africa Check. https://africacheck.org/fbcheck/no-former-us-president-obama-didnt-warn-
africans-against-coronavirus-vaccines/ 
75. Cornwall, W. (2020). Officials gird for a war on vaccine misinformation. Science, 369(6499), 14–15. 
https://doi.org/10.1126/science.369.6499.14 
76. Dror, A. A., Eisenbach, N., Taiber, S., Morozov, N. G., Mizrachi, M., Zigron, A., Srouji, S., & Sela, E. (2020). Vaccine 
hesitancy: The next challenge in the fight against COVID-19. European Journal of Epidemiology, 35(8), 
775–779. https://doi.org/10.1007/s10654-020-00671-y 
77. Grech, V., Gauci, C., & Agius, S. (2020). Vaccine hesitancy among Maltese healthcare workers toward 
influenza and novel COVID-19 vaccination. Early Human Development, 105213. 
https://doi.org/10.1016/j.earlhumdev.2020.105213 
78. Verger, P., & Dubé, E. (2020). Restoring confidence in vaccines in the COVID-19 era. Expert Review of 
Vaccines, 0(0), 1–3. https://doi.org/10.1080/14760584.2020.1825945 
79. Burki, T. (2020). The online anti-vaccine movement in the age of COVID-19. The Lancet Digital Health, 
2(10), e504–e505. https://doi.org/10.1016/S2589-7500(20)30227-2 
80. Kramer, A. E. (2020, August 11). Russia Approves Coronavirus Vaccine Before Completing Tests. The New 
York Times. https://www.nytimes.com/2020/08/11/world/europe/russia-coronavirus-vaccine-
approval.html 
81. Larson, H. J. (2020). Blocking information on COVID-19 can fuel the spread of misinformation. Nature, 
580(7803), 306–306. https://doi.org/10.1038/d41586-020-00920-w 
82. Chappel, B. (2020, September 8). 9 Drugmakers Sign Safety Pledge In Rush To Develop Coronavirus 
Vaccine. NPR. https://www.npr.org/sections/coronavirus-live-updates/2020/09/08/910671322/9-
drugmakers-sign-safety-pledge-in-race-to-develop-covid-19-vaccine 
83. Pfattheicher, S., Petersen, M. B., & Böhm, R. (2020). Information about herd immunity and empathy 
promote COVID-19 vaccination intentions [Preprint]. https://doi.org/10.31234/osf.io/wzu6k 
84. Pennycook, G., McPhetres, J., Zhang, Y., Lu, J. G., & Rand, D. G. (2020). Fighting COVID-19 Misinformation 
on Social Media: Experimental Evidence for a Scalable Accuracy-Nudge Intervention. Psychological 
Science, 31(7), 770–780. https://doi.org/10.1177/0956797620939054 
85. IFRC. (2016). A Red Cross Red Crescent Guide to Community Engagement and Accountability (CEA) . 
https://media.ifrc.org/ifrc/wp-content/uploads/sites/5/2017/12/IFRC-CEA-GUIDE-0612-LR.pdf 
86. Subbarao, K. (2020). COVID-19 vaccines: Time to talk about the uncertainties. Nature, 586(7830), 475–475. 
https://doi.org/10.1038/d41586-020-02944-8 
87. Braunack-Mayer, A. J., Street, J. M., Rogers, W. A., Givney, R., Moss, J. R., Hiller, J. E., & Flu Views team. (2010). 
Including the public in pandemic planning: A deliberative approach. BMC Public Health, 10(1), 501. 
https://doi.org/10.1186/1471-2458-10-501 
 
RAPID REVIEW: VACCINE HESITANCY AND BUILDING CONFIDENCE IN COVID-19 VACCINATION 
Contact:  t.hrynick@ids.ac.uk 18 
 
ACKNOWLEDGEMENTS 
We would like to thank Heidi Larson (Vaccine Confidence Project) and Alex Bowmer 
(LSHTM) for their expert input, as well as Luisa Enria (LSHTM), Magdalena Issauralde 
(RCCE Collective Service), Caroline Austin, Monica Posada and Diana Manilla Arroyo (all 
from IFRC) and members of the SSHAP team for their reviews. 
CONTACT 
If you have a direct request concerning the response to COVID-19, regarding a brief, tools, 
additional technical expertise or remote analysis, or should you like to be considered for 
the network of advisers, please contact the Social Science in Humanitarian Action 
Platform by emailing Annie Lowden (a.lowden@ids.ac.uk) or 
(oliviatulloch@anthrologica.com).  Key Platform liaison points include: UNICEF 
(nnaqvi@unicef.org); IFRC (ombretta.baggio@ifrc.org); and GOARN Research Social 
Science Group (nina.gobat@phc.ox.ac.uk). 
 
 
The Social Science in Humanitarian Action is a partnership between the Institute of 
Development Studies, Anthrologica and the London School of Hygiene and Tropical 
Medicine.  Funding to support the Platform’s response to COVID-19 has been provided by 
the Wellcome Trust and DFID. The opinions expressed are those of the authors and do 
not necessarily reflect the views or policies of IDS, Anthrologica, LSHTM, Wellcome Trust 
or the UK government. 
Suggested citation: Hrynick, T., Ripoll, S., and Schmidt-Sane, M. (2020) ‘Rapid Review: 
Vaccine Hesitancy and Building Confidence in COVID-19 Vaccination’, Briefing, Brighton: 
Social Science in Humanitarian Action (SSHAP)  
Published November 2020© Institute of Development Studies 2020 
This is an Open Access paper distributed under the terms of the Creative 
Commons Attribution 4.0 International licence (CC BY), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original 
authors and source are credited and any modifications or adaptations are indicated. 
http://creativecommons.org/licenses/by/4.0/legalcode 
